<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03528941</url>
  </required_header>
  <id_info>
    <org_study_id>LLC1618</org_study_id>
    <nct_id>NCT03528941</nct_id>
  </id_info>
  <brief_title>The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib</brief_title>
  <acronym>LLC1618</acronym>
  <official_title>Observational Retrospective Multicenter Study Aimed at Evaluating the Incidence of Hepatitis B Reactivation in Patients Affected by Chronic Lymphocytic Leukemia Treated With Ibrutinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational retrospective study will enroll at least 158 patients affected by Chronic
      Lymphoid Leukemia (CLL) with previous HBV exposure (HBsAg negative, anti-HBc positive with or
      without anti-HBs) treated with Ibrutinib single agent according to the IWCLL criteria 2008.
      Patients will be divided into two cohorts, one encompassing patients who received lamivudine
      and the second one including patients who received no prophylaxis. Each patient will be
      observed for one year from the first administration of Ibrutinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This observational retrospective study will enroll at least 158 patients affected by CLL with
      previous HBV exposure (HBsAg negative, anti HBc positive with or without anti-HBs) treated
      with Ibrutinib single agent according to the IWCLL criteria 2008. Patients will be divided in
      two cohorts one encompassing patients receiving lamivudine and the second one including
      patients who will not be given any prophylaxis. Each patient will be observed for one year
      from the first administration of Ibrutinib.

      The aim of the Study is to evaluate the incidence of HBV reactivation cases in patients
      affected by CLL treated with Ibrutinib.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with hepatitis B reactivation</measure>
    <time_frame>After 12 months from the first administration of Ibrutinib</time_frame>
    <description>The primary objective of the Study is to evaluate the incidence of HBV reactivation cases in patients affected by CLL treated with Ibrutinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients managed by prophylaxis</measure>
    <time_frame>After 12 months from the first administration of Ibrutinib</time_frame>
    <description>number of patients managed by lamivudine prophylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients undergoing strict follow-up only</measure>
    <time_frame>After 12 months from the first administration of Ibrutinib</time_frame>
    <description>number of patients who did not receive any prophylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of HBV reactivation according to patient status and prophylaxis</measure>
    <time_frame>After 12 months from the first administration of Ibrutinib</time_frame>
    <description>Incidence of HBV reactivation related to patient clinical, biological and therapeutic characteristics, especially in connection with the different incidence of reactivation in patients who received lamivudine prophylaxis versus patients observed with a strict follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events during ibrutinib treatment</measure>
    <time_frame>After 12 months from the first administration of Ibrutinib</time_frame>
    <description>Safety profile in patients who received lamivudine prophylaxis versus patients observed with a strict follow-up</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Lamivudine</arm_group_label>
    <description>Patients who received lamivudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No prophylaxis</arm_group_label>
    <description>Patients who did not receive any prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Patients who received lamivudine to prevent hepatitis B</description>
    <arm_group_label>Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No prophylaxis</intervention_name>
    <description>Patients who did not receive any prophylaxis to prevent hepatitis B</description>
    <arm_group_label>No prophylaxis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CLL with previous HBV exposure treated with at least one dose of Ibrutinib.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CLL/small lymphocytic lymphoma (SLL) patients.

          -  Patients treated with single-agent Ibrutinib (at least one dose) outside
             interventional clinical trials before January 31, 2019.

          -  Serology positive with previous HBV/OBI (HBsAg negatives, anti-HBc positives with or
             without anti-HBs) infection.

          -  Signed written informed consent, if applicable, indicating study scope and procedure
             understanding.

        Exclusion Criteria:

          -  Patients who did not undergo hepatitis B screening before starting the Ibrutinib
             therapy.

          -  Patients affected by CLL treated with Ibrutinib vaccinated against hepatitis B or with
             serology not compatible with a previous infection.

          -  Patients affected by HCV, HIV or with other causes of liver disease.

          -  Patients enrolled in clinical trials including Ibrutinib administered in combination
             with other drugs.

          -  Patients positive for active hepatitis B.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Laurenti</last_name>
    <role>Principal Investigator</role>
    <affiliation>Università Cattolica del Sacro Cuore - Policlinico A. Gemelli, Roma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>0670390528</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AOU Arcispedale S.Anna - UOC Ematologia e fisiopatologia della coagulazione</name>
      <address>
        <city>Cona</city>
        <state>Ferrara</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Cuneo</last_name>
    </contact>
    <investigator>
      <last_name>GianMatteo Rigolin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Consorziale Policlinico - UO Ematologia con Trapianto</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albano</last_name>
    </contact>
    <investigator>
      <last_name>Albano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST degli Ospedali Civili di Brescia - UO Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Motta</last_name>
    </contact>
    <investigator>
      <last_name>Marina Motta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Brotzu, Presidio Ospedaliero A.Businco - SC Ematologia e CTMO</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murru</last_name>
    </contact>
    <investigator>
      <last_name>Roberta Murru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CTC U.O. di Ematologia con Trapianto di midollo osseo - Catania</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Di Raimondo</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Di Raimondo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO di Catanzaro &quot;Pugliese - Ciaccio&quot;, Presidio Ospedaliero &quot;Ciaccio - De Lellis&quot; - Ematologia</name>
      <address>
        <city>Catanzaro</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molica</last_name>
    </contact>
    <investigator>
      <last_name>Stefano Molica</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS AOU San Martino - UO Ematologia e Trapianti</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ibatici</last_name>
    </contact>
    <investigator>
      <last_name>Adalberto Ibatici</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tedeschi</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra Tedeschi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico - Ematologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reda</last_name>
    </contact>
    <investigator>
      <last_name>Gianluigi Reda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele - Unità neoplasie linfocitarie B</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghia</last_name>
    </contact>
    <investigator>
      <last_name>Paolo Ghia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Maggiore della Carità di Novara - SCDU Ematologia</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaidano</last_name>
    </contact>
    <investigator>
      <last_name>Gianluca Gaidano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo - OU Ematologia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Varettoni</last_name>
    </contact>
    <investigator>
      <last_name>Marzia Varettoni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Pisana - UO Ematologia Universitaria</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petrini</last_name>
    </contact>
    <investigator>
      <last_name>Mario Petrini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Tor Vergata - UOC Trapianto cellule staminali</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Del Poeta</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Del Poeta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A. Gemelli IRCCS - Area Ematologica</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurenti</last_name>
    </contact>
    <investigator>
      <last_name>Luca Laurenti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio Medico - UOC Ematologia e Trapianto di cellule staminali</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>De Muro</last_name>
    </contact>
    <investigator>
      <last_name>Marianna De Muro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza, Ospedale S.Giovanni Battista Molinette - SC Ematologia</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coscia</last_name>
    </contact>
    <investigator>
      <last_name>Marta Coscia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.gimema.it</url>
    <description>GIMEMA Foundation website</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Ibrutinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

